Cellseed Inc. · TSE:7776
Cellseed — FY2024 Earnings Presentation
33 slides from Cellseed's earnings presentation, Mar 31, 2025
Slide 1: Fiscal 2024 Earnings Results Presentation
CellSeed Inc. Fiscal 2024 Earnings Results Presentation Tokyo Stock Exchange Growth Code:7776
Slide 2: Contents
Contents Company Profile Financial Summary of Fiscal Year Ending Year December 31, 2024 Progress of each business © 2024 CellSeed Inc. 1
Slide 3: Head office, CPC, development and manufacturing facility
Head office・CPC・development and manufacturing facility Established May, 2001 Core Cell Sheet Engineering based Telecom Center competence on Temperature Responsive Polymers Listed Tokyo Stock Exchange Growth（7776) Head Office 15F (East Wing) Telecom Center Building 2-5-10, Aomi, Koto-ku, Tokyo Cell P
Slide 4: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Regenerative Medical Regenerative Medicine Products Business Supporting Business Commercialization of Cell Sheet Therapies Intellige
Slide 5: Our Business Model
Our Business Model Medical Hospitals Patients Seeds Products Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partner Companies Delivering the technology developed at a university and developed at a venture to patients as soon as possible. © 2024
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering © 2024 CellSeed Inc. 5
Slide 7: New law related to regenerative medicine, enforced in 2014
New law related to regenerative medicine, enforced in 2014 Act on the Safety of Regenerative Act on Pharmaceuticals and Medicine Medical Devices Law for regulating regenerative medicine, Law for regulating products for etc. performed on the responsibility of regenerative medicine, etc. manufactured
Slide 8: Sources of cells used for regenerative medicine
Sources of cells used for regenerative medicine Autologous Allogeneic Harvesting of Harvesting of Cells of patients cells Cells of others cells ・Somatic cells ・Somatic cells ・Mesenchymal stem ・Mesenchymal stem cells cells ・iPS cells ・iPS cells Donor Administration Administration Merits Merits • Free
Slide 9: Methods for administering products for regenerative medicine, etc.
Methods for administering products for regenerative medicine, etc. To directly administer or To administer a product to implant a product to a the entire body via blood target area for vessels by injection or regeneration by surgery intravenous drip or with an endoscope © 2024 CellSeed Inc. 8
Slide 10: Contents
Contents Company Profile Financial Summary of Fiscal Year Ending Year December 31, 2024 Progress of each business © 2024 CellSeed Inc. 9
Slide 11: Year financial summary FY 12/2024
Year financial summary FY 12/2024 First Half of the First Half of the FY2024 FY2023 (January 2024 - Dec 2024) (January 2023 - Dec 2023) Change from Change from Amount Amount Previous Period Previous Period (Millions of yen) (Millions of yen) (Millions of yen) (%) Sales 193 3 1.7 190 Operating profit
Slide 12: Full-year results in FY 2024
Full-year results in FY 2024 Difference between the forecast [million yen] Initial forecast (A) Full-year result (B) and the result (B – A) Sales 170 193 23 Operating income △920 △846 74 Ordinary income △920 △847 73 Net income △940 △859 81 Both sales and profit exceeded the forecasts. Sales ■The sal
Slide 13: Topics (FY 12/2024)
Topics (FY 12/2024) Cell cultureware business ◼ The sales in the overseas market increased considerably year on year. ◼ The sales of the cell cultureware business grew from the previous fiscal year, hitting a record high. Commissioned regenerative medicine business ◼ We undertook the manufacturing o
Slide 14: Contents
Contents Company Profile Financial Summary Second Quarter of Fiscal Year Ending December 31, 2024 Progress of each business © 2024 CellSeed Inc. 13
Slide 15: Cell Cultureware Business
Cell Cultureware Business UpCell® RepCell® This cultureware In addition to the same maintains the physiological characteristics as those activity of cells and retains of UpCell®, this a high level of antigen cultureware allows for proteins on the cell the recovery of cells in a surface while serving
Slide 16: Variation in sales of the cell cultureware business
Variation in sales of the cell cultureware business Sales have grown 3.5 times over the past eight years. CAGR Continued significant increase in overseas 17.1% sales from last fiscal year. In FY 12/2024, sales hit a record high. In the first half of FY 12/2024 （千円） We received a healthy number of or
Slide 17: Overseas needs for cell cultureware
Overseas needs for cell cultureware Overseas sales account for about 80%. Overseas regenerative medicine ◼ There are an increasing number of cases of cellular therapy against cancer, allergies, and immunity disorder and stem cell treatment. Japan Culturing and Overseas ＞＞＞ collection of a Cell large
Slide 18: Cultivation of new markets for cell cultureware
Cultivation of new markets for cell cultureware Need for technology to culture cells in large quantities ◼ Biopharmaceutical manufacturing Possibility of ◼ Manufacturing cells for use in immunotherapy market expansion ◼ Development of cellular foods such as cultured meat Required number of cells Cul
Slide 19: Regenerative Medicine Contract Manufacturing Services
Regenerative Medicine Contract Manufacturing Services © 2024 CellSeed Inc. 18
Slide 20: Regenerative Medicine Contract Manufacturing Services
Regenerative Medicine Contract Manufacturing Services Serving as a bridge to deliver regenerative medicine to patients by solving problems with academia and closing the gap Acquisition of licenses for manufacturing and sale in accordance with the Act on R&D in academia Pharmaceuticals and Medical De
Slide 21: Regenerative Medicine Contract Manufacturing Services
Regenerative Medicine Contract Manufacturing Services Development of Manufacturing Methods and 1 Contract Manufacturing for Cell Sheet Products ⚫ Development of cell sheet manufacturing methods ⚫ Contract manufacturing of cell sheet products ⚫ Quality testing of cell sheets, etc. 2 Facility Manageme
Slide 22: Commissioned projects in our regenerative medicine service
Commissioned projects in our regenerative medicine service Cell Processing Center ◼ The permission to manufacture specific processed cells (facility No. FA3160008 , March 2017) ◼ The permission to manufacture products for regenerative medicine（October 2018 ） Examples of Contract Services ◼ Autologou
Slide 23: Background for development of allogeneic chondrocyte sheets (CLS2901C)
Background for development of allogeneic chondrocyte sheets (CLS2901C) ◼ Knee osteoarthritis (OA) ⚫ Due to the aging of the population, the number of patients is projected to increase. In clinical research, good results ⚫ There is no definitive treatment method. were observed in all of 10 cases. Tra
Slide 24: Manufacturing process of allogeneic chondrocyte sheets (CLS2901C)
Manufacturing process of allogeneic chondrocyte sheets (CLS2901C) Cell Bank Fingers removed from polydactyly patients Isolated cartilage Seeding Cryopreservation Passage culture P0 P1 Cell Stock (Master Cell Bank) Px Working Cell Bank Safety Safety Safety Cell Sheets Transplant Preculture Sheet form
Slide 25: Quality test items for cell banks and cell sheets
Quality test items for cell banks and cell sheets Tests for cell count, ratio of living cells, aseptic conditions, endotoxin, Cell Bank response to mycoplasma and viruses, etc. Fingers removed from polydactyly patients Isolated cartilage Seeding Cryopreservation Passage culture P0 P1 Cell Stock (Mas
Slide 26: Phase III clinical trials of allogeneic chondrocyte sheets
Phase III clinical trials of allogeneic chondrocyte sheets Subjects: patients with knee osteoarthritis who should undergo high tibial osteotomy (HTO) Flowchart of treatments 1 month after an operation and thereafter 1 year after an operation Discharge Implant Registration Exam, etc. Operation from h
Slide 27: U.S. patent related to allogeneic chondrocyte sheets
U.S. patent related to allogeneic chondrocyte sheets In response to the application for the following U.S. patent related to allogeneic chondrocyte sheets, a decision to grant a patent has been made. ◼ U.S. patent application No. 17/729,608 ◼ Title of the invention: a cultured cell sheet for tissue
Slide 28: Exhibitions, research presentations, etc. at academic conferences in 2024
Exhibitions, research presentations, etc. at academic conferences in 2024 The Japanese Society for Regenerative Medicine (luncheon, poster, and corporate exhibition; Mar. 21-23, 2024) The Pharmaceutical Society of Japan (corporate exhibition; Mar. 28-30, 2024) Japanese Research Group on Knee Osteoto
Slide 29: Participation in academic conferences, etc.
Participation in academic conferences, etc. Congress of the Japanese Society for Regenerative Medicine Date: Thursday, March 21 to Saturday, March 23 Place: Toki Messe (Niigata) ◼ Corporate exhibition ◼ Co-hosted academic seminar © 2024 CellSeed Inc. 28
Slide 30: Participation in academic conferences, etc.
Participation in academic conferences, etc. Regenerative Medicine EXPO Date: Wednesday, June 26, 2024; 14:00 to 15:00 Place: Tokyo Big Sight ◼ Special lecture 2 at Regenerative Medicine EXPO Round-table talk: regarding regulations on all phases from clinical trials to after-sales care for products f
Slide 31: We will participate in Regenerative Medicine JAPAN
We will participate in Regenerative Medicine JAPAN Dates: Wed., Oct. 9 to Fri., Oct. 11, 2024 Venue: Pacifico Yokohama ◆ Exhibition booth ◆ Presentations by exhibitors © 2024 CellSeed Inc. 30
Slide 32: To hold the 4th Cell Sheet Engineering Innovation Forum
To hold the 4 th Cell Sheet Engineering Innovation Forum Date: Fri., Nov. 28, 2025 Venue: Miraikan Hall on the 7th floor of Miraikan, etc. No. of attendees: up to 200 (Pre-registration required; first-come-first-served) Attendance fee: Free Lectures by invited professors, et al. Professor Tatsuya Sh
Slide 33: This presentation is made by CellSeed Inc. solely for the disclosure of the financial
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. © 2024 CellSeed Inc. 32